Most Read

Italian pharmaceutical company Fidia Farmaceutici has signed a binding agreement to acquire an integrated portfolio of anti-inflammatory drugs from Sanofi. Under the terms of the agreement, Fidia will

Zealand Pharma has announced the US Food and Drug Administration (FDA) approval of its Zegalogue (dasiglucagon) injection for the treatment of patients aged six and above with severe

US-based global biotechnology company Dyadic International has announced the expansion of its partnership with South Korea-based global research biopharmaceutical company Medytox to co-develop C1 manufactured Covid-19 vaccines. Dyadic’s

Johnson & Johnson’s Janssen Pharmaceutical Companies have announced the US Food and Drug Administration (FDA) approval of PONVORY for the treatment of relapsing forms of multiple sclerosis (MS)

Anima Biotech has announced its new strategic collaboration deal with Takeda Pharmaceutical Company for the discovery and development of new medicines to combat genetically defined neurological diseases. The

The US-based clinical stage biopharmaceutical company Boston Pharmaceuticals has announced the signing of a unique three-year out-license and option agreement with the UK-based GlaxoSmithKline (GSK). With this agreement,

The US Food and Drug Administration (FDA) grants orphan drug designation to Ambrx for ARX788, a homogeneous and highly stable antibody drug conjugate, for the treatment of HER2-positive

The US Food and Drug Administration (FDA) has extended the review period for AbbVie’s supplemental New Drug Application (sNDA) for upadacitinib. The global R&D-based biopharmaceutical company’s new drug

The UK’s Cambridge-based biopharma company AstraZeneca will be delivering 500,000 more doses of AZD7442 to the US after having modified an existing agreement with the US Government. AstraZeneca’s